[ad_1]
Antibiotice Iaşi won the competition organized by the European Commission for the product AmoxiPlus (amoxicillin / clavulanic acid – sterile injectable powder) and will deliver 2.75 million vials in a period of 12 months.
The European Commission has recently finalized the tender to provide member countries with the necessary stocks for the second wave of the pandemic with beta-lactam antibiotics (amoxicillin with clavulanic acid and piperacycline with tazobactam).
“I believe that each of us has to do what we do best. Antibiotice provides Europe with an extremely important strategic product for the treatment of COVID-19-associated infections. We won the auction with a common sense price of 1.19 euros / bottle, giving access to this product to European countries Amoxicillin with clavulanate is one of the most valuable drugs to fight bacterial infections and more. At Antibiotice we have 65 years of experience and knowledge in the production of sterile injectable powders. However, beyond providing what is necessary with AmoxiPlus from the European markets, deliveries will be made considering first the coverage of the need for anti-infective drugs for Romanian patients. We respect our contracts, ensuring the continuity of deliveries to our partners national ”, said Ioan Nani, general manager of Antibiotice Iaşi.
Amoxicillin with clavulanic acid, together with piperacycline with tazobactam, are the main products recommended by the World Health Organization for anti-infective treatment.
Winning the auction implied obtaining a maximum score by cumulatively meeting four essential conditions: quality, validity, price, speed / punctuality in delivery.
Antibiotice Iași is the only pharmaceutical company in Romania that has a production flow of sterile injectable powders, the first product was manufactured in 1955. The quality standards implemented in this production flow have been recognized and approved by the FDA (Food Administration and Medications) from the US, More shows the cited source.
The Iași company mentions that it markets this top-generation antibiotic, produced for over 30 years, in hospitals in Romania, Great Britain, Vietnam, Hungary, Lithuania, Iraq, Yemen.
Publisher: GC
